Skip to content
Aging — Science — Neuroimaging — Neurodegeneration — Brain activity — Medical-conditions — Health-and-wellness — Neuroscience news — Mood disorders

Selective Serotonin Reuptake Inhibitors (SSRIs) Improve Brain Function in Alzheimer's Patients.

Research finds potential for commonly used antidepressants, SSRIs, in lowering indicators of Alzheimer's.

,   and  Administrator
3 min read
Antidepressants known as SSRIs could potentially lower indicators of Alzheimer's disease, according...
Antidepressants known as SSRIs could potentially lower indicators of Alzheimer's disease, according to fresh research findings.

Selective Serotonin Reuptake Inhibitors (SSRIs) Improve Brain Function in Alzheimer's Patients.

A study published in Alzheimer's & Dementia suggests that long-term use of selective serotonin reuptake inhibitors (SSRIs), a class of antidepressants, might help reduce the biological signs of Alzheimer's disease (AD).

Researchers found that patients with AD who were on SSRI therapy exhibited lower levels of a blood-based marker of tau pathology, known as phosphorylated tau-181 (p-tau181), compared to those not taking antidepressants. This reduction in p-tau181 suggests a potential protective effect of SSRIs on tau pathology.

Brain scans revealed that the dorsal raphe nucleus (DRN), a serotonin-rich region deep within the brainstem and one of the earliest sites of tau accumulation in AD, is typically hypometabolic, or underactive, in AD patients. However, those on SSRIs showed restored glucose metabolism in this region, indicating revived neural function.

The research team, which analyzed data from 191 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), noted that this metabolic recovery in the DRN was specific to AD patients. Healthy control participants showed no change in DRN metabolism with SSRI treatment.

Although promising, the effects of SSRIs on cognitive performance were mixed, with some improvements visible only in certain cognitive tests, like the Montreal Cognitive Assessment (MoCA), while others showed no demonstrable improvement.

Intriguingly, the usual correlation between different cognitive assessments was disrupted in SSRI users, implying that antidepressants may impact how cognitive decline is measured rather than its progression.

This cross-sectional study cannot establish cause and effect and did not take into account the types or dosages of SSRIs used or whether treatment commenced before or after AD symptoms appeared. The researchers emphasized that further clinical trials are needed to investigate the timing, duration, and cognitive impact of SSRI treatment in neurodegenerative diseases.

The study adds to growing evidence that the brain's serotonin system intertwines closely with Alzheimer's pathology. While SSRIs are primarily prescribed for mood disorders, they may also influence key processes in Alzheimer's, such as the metabolism of vulnerable brain regions and the spread of toxic proteins. As researchers continue exploring the connection between mood, memory, and brain chemistry, SSRIs may prove to be a surprising ally in the fight against cognitive decline.

In terms of other studies and approaches related to the topic:

Recent research has looked into modulating brain cortisol levels using Xanamem, a drug that has shown promise in treating both depression and Alzheimer's disease[4][5]. While this is not directly related to SSRIs, it highlights innovative approaches targeting neurodegenerative diseases.

For ongoing studies focused on SSRI treatment in Alzheimer's disease, consult databases like ClinicalTrials.gov or the Alzheimer's Association Clinical Trials Matching Service. These resources can provide information on trials examining the timing, duration, and cognitive impact of SSRI treatment in Alzheimer's disease.

  1. The study published in Alzheimer's & Dementia suggests that long-term use of selective serotonin reuptake inhibitors (SSRIs) could potentially help reduce the biological signs of Alzheimer's disease (AD).
  2. Researchers found that patients with AD who were on SSRI therapy exhibited lower levels of a blood-based marker of tau pathology, known as phosphorylated tau-181 (p-tau181), compared to those not taking antidepressants.
  3. Brain scans revealed that the dorsal raphe nucleus (DRN), a serotonin-rich region deep within the brainstem and one of the earliest sites of tau accumulation in AD, is typically hypometabolic in AD patients.
  4. However, those on SSRIs showed restored glucose metabolism in this region, indicating revived neural function.
  5. Although promising, the effects of SSRIs on cognitive performance were mixed, with some improvements visible only in certain cognitive tests, like the Montreal Cognitive Assessment (MoCA).
  6. Intriguingly, the usual correlation between different cognitive assessments was disrupted in SSRI users, implying that antidepressants may impact how cognitive decline is measured rather than its progression.
  7. This cross-sectional study did not establish cause and effect and did not take into account the types or dosages of SSRIs used or whether treatment commenced before or after AD symptoms appeared.
  8. Researchers highlighted the need for further clinical trials to investigate the timing, duration, and cognitive impact of SSRI treatment in neurodegenerative diseases.
  9. Recent research has explored modulating brain cortisol levels using Xanamem, a drug that has shown promise in treating both depression and Alzheimer's disease, which is not directly related to SSRIs but highlights innovative approaches targeting neurodegenerative diseases.

Read also:

    Related

    Latest